Courtesy of Benzinga.
Shares of Amarin (NASDAQ: AMRN) have surged another 17% on Friday amid takeover rumors and optimism about a U.S. patent for the company’s lead drug candidate AMR-101. Yesterday, I noted that a takeover could come at a large premium to current prices. Another possibility is that Amarin could strike a partnership deal with a larger pharmaceutical company.
On Friday, the stock is trading at $10.49, a new multi-month high. Volume has been extremely heavy with more than 17 million AMRN shares trading hands compared to a 3-month daily average of 3.1 million.
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.
